Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical trial seeking a treatment for depression which has failed to meet its primary endpoint. In our fast-paced world, balancing a busy work schedule with life’s inevitable ups and downs can be challenging. Drugs for cognitive
Read More
A standoff with shareholders dating back to 2014 has finally ended with Mayne Pharma (ASX: MYX) agreeing to settle a class action brought against them from shareholders, centering around allegations of misleading and deceptive conduct by the pharma company. The origins of the class action trace back to investigations by the US Department of Justice
Read More
Pharmaceutical and healthcare company Vita Life Sciences (ASX: VLS) has forecasted a positive growth trajectory for the first half of CY24. Besides expecting sales growth, it is also expecting returns from its recent product launch in Vietnam. The Company expects sales to rise to between $39 million and $40 million, up from $34.7 million in
Read More
Pharmaceutical company Firebrick Pharma (ASX: FRE)’s Nasodine Nasal Spray has been launched in the United States and can now be purchased from the Company’s US website with online promotions will commencing this week across the US. In the US, Nasodine will be promoted for ‘nasal hygiene’ without any therapeutic claims. Based on legal advice obtained
Read More
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) is conducting a clinical trial—the ACCENT trial—for pancreatic cancer. The trial will test a new drug called narmafotinib in combination with standard chemotherapy. Narmafotinib targets a protein called FAK (Focal Adhesion Kinase), which is becoming a hot area of research in cancer treatment. Amplia’s drug aims to make
Read More
For the second time this year, pharma company AFT Pharmaceuticals (ASX: AFP) has bagged the US Food and Drug Administration’s (FDA) approval. In March 2023, it was approved for Maxigesic Rapid, a rapid-release tablet for acute pain. This time, it’s for Maxigesic IV, the intravenous form of its patented pain relief medicine. The approval was
Read More